Advertisement

<a href="//cdm-d.openx.net/w/1.0/rc?cs=ede153ebee&cb=190064118"> <img src="//cdm-d.openx.net/w/1.0/ai?auid=538187993&cs=ede153ebee&cb=190064118" border="0" alt=""></a>

#Vemlidy

Gilead’s float in the Seattle LGBT pride parade, June 2017

Is Gilead’s Entire HIV Enterprise Built on a False Promise?

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

EASL 2017 Roundup: Continued Progress in Fighting Liver Disease

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

Advertisement

<a href="//cdm-d.openx.net/w/1.0/rc?cs=ede153ebee&cb=197364339"> <img src="//cdm-d.openx.net/w/1.0/ai?auid=538187994&cs=ede153ebee&cb=197364339" border="0" alt=""></a>